← Leaderboards
Pier P Scaglioni
University Of Cincinnati
$5,571,751
Attributed
$5,790,782
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $832.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,790,782 · 5
By mechanism
R01$3,160,595 · 2
P50$1,522,660 · 1
K08$669,465 · 1
T32$438,062 · 1
Top collaborators
- Xiaoyang Qi1 shared
Most similar at University Of Cincinnati
Same institution · by research overlap
- Christina A Wicker$300,144
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelTumorMutantOncogenicNon-Small-Cell Lung CarcinomaCancer TherapyCancer CellMalignant Neoplasm Of LungOncogenesMediatingMalignant NeoplasmsTumorigenesisNovel TherapeuticsSignal TransductionIn VivoDrug TargetingEffective TherapyPre-Clinical ModelTransgenic MiceInhibitor/AntagonistMutationLungCancer EtiologyCessation Of Life
Grant awards (21)
Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancer$402,035
R01 · FY2025 · CA · contact PI
Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancer$381,935
R01 · FY2024 · CA · contact PI
Post-Graduate Hematology/Oncology Translational (PG-HOT) Training Program$438,062
T32 · FY2023 · CA · contact PI
Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancer$393,994
R01 · FY2023 · CA · contact PI
Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancer$402,035
R01 · FY2022 · CA · contact PI
Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC$318,713
P50 · FY2018 · CA · contact PI
Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC$318,714
P50 · FY2017 · CA · contact PI
Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC$299,590
P50 · FY2016 · CA · contact PI
Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC$283,131
P50 · FY2015 · CA · contact PI
Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC$302,512
P50 · FY2014 · CA · contact PI
Characterization and drug targeting of the PML tumor suppressor in lung cancer$297,042
R01 · FY2013 · CA · contact PI
Characterization and drug targeting of the PML tumor suppressor in lung cancer$316,002
R01 · FY2012 · CA · contact PI
Characterization and drug targeting of the PML tumor suppressor in lung cancer$316,002
R01 · FY2011 · CA · contact PI
Characterization and drug targeting of the PML tumor suppressor in lung cancer$325,775
R01 · FY2010 · CA · contact PI
Characterization and drug targeting of the PML tumor suppressor in lung cancer$325,775
R01 · FY2009 · CA · contact PI
Post-transcriptional regulation of PML function$133,893
K08 · FY2009 · CA · contact PI
Post-transcriptional regulation of PML function$133,893
K08 · FY2008 · CA · contact PI
Post-transcriptional regulation of PML function$133,893
K08 · FY2007 · CA · contact PI
Post-transcriptional regulation of PML function$105,999
K08 · FY2006 · CA · contact PI
Post-transcriptional regulation of PML function$27,894
K08 · FY2006 · CA · contact PI
Post-transcriptional regulation of PML function$133,893
K08 · FY2005 · CA